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Aging is a complex biological process controlled by 
both environmental and genetic factors [1]; however, 
twin studies suggest 20-30% of lifespan variation is 
genetic [2, 3]. Altering the activity or expression of 
specific genes significantly impacts lifespan in animal 
models [4]. For example, increased expression of the 
protein deacetylase Sirt1 is known to slow the effects of 
aging and increase lifespan [5]. In contrast, reduced 
levels of the oncogenic transcription factor c-Myc 
(Myc), due to heterozygosity, was recently reported to 
significantly increase longevity in mice [6-8].   
 
Myc is estimated to transcriptionally regulate 10-15% 
of the genome [9, 10]. While Myc has been implicated 
in processes such as stem cell maintenance, differentia-
tion, and apoptosis, Myc transcriptional activity is 
closely linked to cell-cycle progression and the vast 
metabolic machinery required  for  cellular  proliferation 
 
[6, 7, 11]. Notably, Myc regulates mitochondrial 
biogenesis through expression of genes such as Pgc1α 
and Pgc1β (peroxisome proliferation activated receptor 
gamma coactivator 1-alpa and beta), providing 
sufficient mitochondria to maintain increased cellular 
metabolism [12].  Myc increases overall cellular energy 
flux by upregulating glycolysis and glutaminolysis 
through transcriptional activations of target genes like 
hexokinase 2 (Hk2) and glutaminase (Gls; [13-16]). The 
energy generated from these metabolic pathways is then 
utilized by downstream pathways regulated by Myc to 
generate critical macromolecules. For example, Myc 
regulates urea cycling and pyrimidine synthesis, via 
transcriptional regulation of ornithine decarboxylase 
(Odc) and carbamoyl-phosphate synthetase 2/aspartate 
transcarbamylase/dihydroorotase (Cad), respectively 
[17, 18].  Myc also increases overall protein synthesis 
[19], a known modulator of longevity [20], through 
regulation of genes like nucleolin (Ncl) that control 
ribosomal assembly [21].   




















expression of Myc  inhibited many of the deleterious effects of aging and  increased  lifespan  in mice. Without
altering  Myc  expression,  reduced  levels  of  Mtbp,  a  recently  identified  regulator  of  Myc,  limit  Myc
transcriptional activity and proliferation, while  increased  levels promote Myc‐mediated effects. To determine
the contribution of Mtbp to the effects of Myc on aging, we studied a large cohort of Mtbp heterozygous mice




system,  and  an  altered  tumor  spectrum  compared  to Mtbp+/+ mice.  Therefore,  the  data  suggest Mtbp  is  a
regulator of longevity in mice that mimics some, but not all, of the properties of Myc in aging.  
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Based on the broad control Myc exerts over cellular 
processes relevant to aging and the recent publication 
directly linking Myc to longevity [8], proteins that 
regulate Myc represent potential modulators of the 
aging process. We recently reported that Mtbp is a Myc 
transcriptional co-factor [22]. In mice, Mtbp 
heterozygosity resulted in reduced Mtbp protein 
expression without altering Myc levels, and this 
inhibited Myc-mediated transcriptional activation of 
target genes, proliferation, and B cell lymphoma 
development [23]. Knockdown of Mtbp expression 
delayed cell cycle progression through S and G2/M 
phases of the cell cycle [24, 25]. In contrast, elevated 
Mtbp expression increased the number of cells in S-
phase and enhanced Myc-mediated transcription and 
tumor development [22].  These data indicate Mtbp is a 
positive regulator of Myc transcriptional activity and 
downstream biological functions. Thus, we tested 
whether reduced Mtbp expression would alter aging in 




Mtbp+/- mice have increased longevity 
 
Since Myc+/- mice have increased longevity [8] and we 
have shown that Mtbp is a positive regulator of Myc 
[22, 23], we investigated the contribution of Mtbp to 
longevity using a cohort of littermate-matched Mtbp+/+ 
and Mtbp+/- mice. Mtbp heterozygous mice had 
increased longevity compared to wild-type controls, 
exhibiting a median survival of 785 days compared to 
654 days (p=0.0013; Figure 1A, Supplemental Figure 
S1), a 20% increase. This significant difference in 
lifespan was represented in both male and female 
populations (Figure 1B and 1C).  Mtbp heterozygous 
males had a median survival of 774 days, compared to 
672 days for wild-type control males (p=0.0166, 
Supplemental Figure S1), a 15.2% increase. Mtbp+/- 
females had a median survival of 790 days, compared to 
650.5 days for Mtbp+/+ females (p=0.0439), a 21.4% 
increase (Supplemental Figure S1).  
 
In addition to median lifespan, Mtbp heterozygosity also 
increased maximum lifespan.  Specifically, Mtbp+/- 
mice were overrepresented in the longest living decile 
and quartile of mice with 9 of 11 (81.8%) and 19 of 26 
(73.1%) of the mice, respectively (Figure 1D). The 
trend was not affected by gender, as the longest living 
decile and quartile of mice were 4 of 5 (80.0%) and 9 of 
12 (75.0%) heterozygous males, respectively, and 4 of 5 
(80.0%) and 10 of 13 (76.9%) heterozygous females, 
respectively.  In contrast, Mtbp wild-type mice (all mice 
and both male and female) were disproportionally 
represented in the shortest lived decile and quartile of 























































was also reflected in the observation that Mtbp+/- mice 
have a significantly decreased instantaneous death rate 
Figure 1.  Mtbp heterozygosity increases longevity.  (A‐C)
Kaplan‐Meier  survival  curves of Mtbp+/+  (+/+) and Mtbp+/‐  (+/‐)
mice with  the number of mice  in each group denoted by n.   p
value  determine  by  log‐rank  tests.  (D)  All,  male,  and  female
Mtbp+/‐ mice  in  the  indicated  decile  or  quartile  of  the mouse
cohort.  (E) Instantaneous death rate plotted; log‐rank p=0.0013,
Chi‐sq=10.27, df=1; number of mice in each group denoted by n.
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compared to Mtbp+/+ littermate-matched controls (log-
rank p=0.0013, Chi-sq=10.27, df=1; Figure 1E). Both 
Mtbp heterozygous males and females have a 
significantly reduced instantaneous death rate (log-rank 
p=0.0166, Chi-sq=5.74, df=1 and log-rank p=0.0439, 
Chi-sq=4.06, df=1, respectively; Supplemental Figure 
S2).  Therefore, an Mtbp haploinsufficiency confers 
increased median and maximum survival. 
 
Delay in tumorigenesis and a change of tumor 
spectrum in Mtbp heterozygous mice 
 
As is commonly seen in C56Bl/6 mice [26, 27], gross 
and histopathological tissue analysis at time of death of 
representative mice demonstrated the majority had 
cancer (17 of 23 Mtbp+/+ mice and 29 of 34 Mtbp+/- 
mice). Notably, 32.4% (11 of 34) of Mtbp+/- mice had 
lymphoma, which was twice the incidence of lymphoma 
in Mtbp+/+ mice (17.4%, 4 of 23; Figure 2A).  The 
lymphomas were detected at an average age of 840 days 
in heterozygotes, compared to 682.3 days in wild-type 
controls, a significant delay (p=0.0320, Supplemental 
Figure S1).  Similarly, Mtbp+/- mice developed 
carcinomas later in life at 848 days (3 of 34, 8.8%) 
compared to 694 days for Mtbp+/+ mice (3 of 23, 13.0%) 
and the tissue distribution of the carcinomas differed 
between the two genotypes. Specifically, two 
carcinomas that developed in the wild-type mice were 
hepatocellular carcinoma and one was a carcinoma of 
the small intestine, whereas two of the Mtbp hetero-
zygous mice developed aural squamous cell carcinoma 
and one had pulmonary adenocarcinoma. The difference 
in age of carcinoma development and the type of 
carcinoma that emerged between the two genotypes was 
not statistically significant likely due to the small 
number of carcinomas that developed (p=0.1412; 
Supplemental Figure S1, Figure 2B). In contrast, 



















age of onset of sarcoma. Approximately half of the 
cancers that developed in both genotypes of mice were 
sarcoma [10 of 23 (43.5%) for Mtbp+/+ and 15 of 34 
(44.1%) for Mtbp+/-; Figure 2C], occurring at a mean 
age of 806 days for Mtbp+/+ and 743 days for Mtbp+/- 
mice (p = 0.1547, Supplemental Figure S1).  The vast 
majority of the sarcomas in both the wild-type and Mtbp 
heterozygous mice were histiocytic sarcomas. One 
Mtbp wild-type mouse developed both a sarcoma and a 
carcinoma, and all Mtbp+/- mice that were diagnosed 
with a malignancy had only one tumor type. Although, 
twice the proportion of Mtbp wild-type control mice 
were cancer free at time of death (7 of 23, 30.4%) 
compared to Mtbp heterozygous mice (5 of 34, 14.7%; 
Figure 2D), the Mtbp+/- mice lived an average of 836.4 
days compared to 640.3 days for wild-type controls 
(Supplemental Figure S1). This difference in Mtbp+/- 
mice represents a significant delay in mortality among 
cancer free mice (p=0.03340). These data collectively 
indicate a decrease in Mtbp expression alters the tumor 
spectrum and age of onset as mice age, as well as 
extends overall survival independent of cancer 
development.      
    
Mtbp+/+ and Mtbp+/- mice move, reproduce, and 
develop similarly 
 
Long-lived mouse models will often retain elevated 
motor function compared to controls, particularly as 
they age. To determine if Mtbp heterozygosity 
improved locomotor activity, open field testing was 
performed for 1 hour on two days with a cohort of old 
(1.5 year) littermate matched mice. Although there was 
a trend for Mtbp heterozygotes to travel a greater 
distance (5737.7 cm) compared to wild-type controls 
(4551.0 cm), this difference did not reach statistical 
significance (p=0.1142; Figure 3A).  When locomotor 
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durance test, the Mtbp+/- mice (78.0 seconds) performed 
similarly to Mtbp+/+ mice (73.6 seconds) after 
training (Figure 3B; p=0.3923). Analogous results 
were also obtained with younger mice (Supplemental 




















































In nature, many animal species with increased longevity 
have reduced reproductive capacity to limit 
overpopulation. This trend has been reported in some 
long-lived mouse models [28]. Thus, we compared the 



















































Figure 4.      Long‐lived Mtbp heterozygous mice exhibit normal systemic physiology.    (A)  The mean




measured with  electronic  calipers  and  averaged  (p=0.7160;  n=7  for  +/‐  group  due  to  loss  of  one  femur  from
bilateral  fracture  from collection).  (D‐H) Blood was collected and serum  isolated. Circulating  levels of  (D)  IGF‐1
(p=0.4175),  (E) cholesterol  (p=0.3572),  (F)  triglycerides  (p=0.4037),  (G) blood glucose  (p=0.7116) and  (H)  insulin
(p=0.6963) were measured. P values calculated with student’s t‐tests, and error bars are SEM.   
Figure 3.   Mtbp heterozygosity does not significantly alter
locomotor activity  in old mice.    (A) Mtbp+/+  (+/+;  circle)  and




rod  was  recorded  and  averaged  from  three  consecutive  trials
separated by 10 minutes of  rest  (p=0.3923).   P values  calculated
with student’s t‐tests and error bars are SEM.   
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mice. Only the number of pups per birth from crosses 
between Mtbp+/+ and Mtbp+/- mice were quantified, as 
deletion of Mtbp is embryonic lethal and would 
artificially lower the number of pups birthed [29]. This 
examination did not reveal a significant difference in 
the average number of pups per litter birthed by Mtbp+/+ 
(6.6) and Mtbp+/- (7.3) females (p=0.2247; Figure 4A). 
 
Some long-lived mouse models reported to have reduced 
growth, resulting in smaller body size [30]. We detected 
no size differences in mature Mtbp+/- mice. Specifically, 
Mtbp+/+ and Mtbp+/- mice had similar nose-to-rump 
lengths of 9.89 cm and 9.74 cm, respectively (p=0.9999; 
Figure 4B) as well as femur lengths of 15.0 mm and 14.8 
mm, respectively (p=0.7160; Figure 4C) at the time of 
sacrifice. Given this observation, it was not surprising 
that analysis of serum isolated and frozen at time of 
sacrifice did not show a statistically significant difference 






































(IGF-1; p=0.4175; Figure 4D), a major growth-promot-
ing factor [31]. Therefore, an Mtbp haploinsufficiency 
did not impact locomotion, birth rates, or bone size.  
 
Long-lived Mtbp+/- mice exhibit signs of increased 
cellular metabolism 
 
Many long-lived mouse models have changes in 
metabolism detectable at a systemic level. To determine 
if Mtbp expression modulates levels of circulating 
metabolic markers, serum was isolated and frozen 
immediately after sacrifice of long-lived mice starved 
for 5 hours. The analysis revealed Mtbp+/+ and Mtbp+/- 
mice had similar levels of serum cholesterol (p=0.3572; 
Figure 4E) and triglycerides (p=0.4037; Figure 4F). 
Moreover, the circulating level of glucose (p=0.7116; 
Figure 4G) and insulin (p=0.6963; Figure 4H) were also 
similar, reflecting no major changes in physiologic 







































Figure  5.    Old  Mtbp  heterozygous  mouse  livers  exhibit  global  elevated  metabolic  markers.  (A‐H)  Healthy
Mtbp+/+  (+/+; n=5; black) and Mtbp+/‐  (+/‐; n=9; gray) mice at 29 months were starved  for 5 hours,  sacrificed, and  livers
frozen with Wallenburg clamp. qRT‐PCR for (A) glutaminase (Gls, p=0.1147), (B) hexokinase 2 (Hk2, p=0.1401), (C) ornithine











































Although systemic changes in cholesterol, triglyceride, 
and glucose metabolism were not observed, we 
examined markers of cellular metabolism in tissues of 
long-lived mice to determine if decreased Mtbp 
expression modulates metabolism at a molecular level. 
Using flash frozen tissue at the time of sacrifice, mRNA 
was isolated from the liver, skeletal muscle 
(gastrocnemius) and brown fat pad of long-lived mice.  
In the liver, Mtbp+/- mice exhibited a global trend 
toward, and at times significantly, increased expression 
of metabolic markers (Figure 5), similar to previous 
reports for Myc+/- mice [8]. Mtbp heterozygosity 
resulted in a trend toward increased expression of basic 
metabolic genes such as Gls, Hk2, Ncl, Cad, and Odc 
that control cellular energy flux, protein translation, and 
macromolecule synthesis (Figure 5A-E). Most notably, 
the livers of Mtbp+/- mice showed a nearly 2-fold and 







































Pcg1α (p=0.0106; Figure 5F) and Pcg1β (p = 0.0499; 
Figure 5G) compared to wild-type controls. This 
increase suggests elevated mitochondrial biogenesis and 
function in long-lived Mtbp heterozygous mice.  These 
increased levels of metabolic markers in Mtbp+/- livers 
also coincided with a nearly 60% increase in the 
expression of Sirt1 (p=0.1529; Figure 5H), a well-
known anti-aging gene linked to caloric restriction [32]. 
 
The global increase in metabolic markers observed in 
the livers of Mtbp heterozygous mice was largely not 
recapitulated in skeletal muscle (Figure 6) and brown 
fat (Figure 7).  In skeletal muscle for example, there 
was only a statistically significant increase in the level 
of Cad in Mtbp+/- mice (p=0.0202), but analogous levels 
of Gls, Hk2, Odc, and Ncl compared to Mtbp+/+ mice 
(Figure 6A-E).  There was a trend toward significantly 
decreased expression of Pcg1α (p=0.0736; Figure 6F) 
Figure 6.   Skeletal muscle  in old Mtbp+/‐ mice  lack global metabolic marker  increase. (A‐H) Healthy
Mtbp+/+  (+/+; n=5; black) and Mtbp+/‐  (+/‐; n=8; gray) mice at 29 months were starved  for 5 hours, sacrificed,
and gastrocnemius muscle frozen with Wallenburg clamp. qRT‐PCR for (A) glutaminase (Gls, p=0.5591; +/‐ n=7
due  to  RNA  loss),  (B)  hexokinase  2  (Hk2,  p=0.  9792),  (C)  ornithine  decarboxylase  (Odc,  p=0.5115),  (D)
carbamoyl‐phosphate synthetase 2/aspartate transcarbamylase/dihydroorotase, (Cad, *p=0.0202), (E) nucleolin
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and Pcg1β (p=0.0710; Figure 6G), but similar levels of 
Sirt1 (Figure 6H) in Mtbp heterozygous skeletal muscle.  
In brown fat, levels of Gls, Hk2, Odc, Cad, and Ncl 
were similar between wild-type and heterozygous Mtbp 
mice (Figure 7A-E). However, the brown fat of Mtbp+/- 
mice exhibited a trend toward increased expression of 
Pcg1α (p=0.0531; Figure 7F), but equivalent levels of 
Pcg1β (p=0.8492; Figure 7G). The levels of Sirt1 were 
analogous between the two genotypes (Figure 7H). 
Therefore, the data show Mtbp heterozygosity alters 
markers of cellular metabolism in disparate tissues, 




We reported that Mtbp is a positive regulator of Myc 
transcriptional activity, promoting Myc-mediated 
proliferation and malignant transformation [22, 23].  
Yet, it was unclear if Mtbp expression contributed to 
Myc-modulation of aging that was recently reported [8]. 



































heterozygosity, significantly increased the median and 
maximum lifespan of mice and delaying cancer 
development compared to wild-type littermate-matched 
controls. The increase was observed regardless of 
gender. These results indicate Mtbp has a significant 
role in aging. 
 
While cancer was the cause of death in the majority of 
mice, reduced Mtbp expression was associated with an 
increased, but significantly delayed, incidence of 
lymphoma. We observed a similar delay in lymphoma 
development in Eμ-myc transgenic mice that were 
Mtbp+/- [23]. Interestingly, Myc+/- mice, also had an 
increase in the rate of lymphoma, although to a much 
less degree, along with significantly reduced 
progression of disease at time of death [8]. In addition 
to delayed lymphoma development, there was also a 
trend for Mtbp+/- mice to have delayed carcinoma 
development. However, Mtbp heterozygous and wild-
type mice had a similar age of onset of sarcoma 






































and  brown  fat  frozen.  qRT‐PCR  for  (A)  glutaminase  (Gls,  p=0.4982),  (B)  hexokinase  2  (Hk2,  p=0.4555),  (C)  ornithine
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cancer types appears to be more impacted than others 
by Mtbp heterozygosity. Specifically, the data suggest 
the hematopoietic compartment may be more sensitive 
to changes in Mtbp expression than other tissues. 
However, in human cancer, MTBP is amplified and/or 
overexpressed in a range of malignancies, including 
lymphomas, carcinomas, and sarcomas, suggesting it is 
oncogenic in multiple tissue types [22, 23, 33]. Future 
studies of Mtbp function comparing different normal 
and cancerous tissues should clarify those cell types in 
which altered Mtbp levels have a significant impact.   
   
Our data that sarcomas present at a similar age suggest 
the overall survival difference between Mtbp+/- and 
Mtbp+/+ mice does not appear to be due to an overall 
delay in cancer development. Additionally, fewer 
Mtbp+/- mice were cancer-free at the time of death, a 
result not predicted had Mtbp only impacted longevity 
by decreasing and/or delaying cancer development. 
Notably, cancer-free Mtbp+/- mice lived significantly 
longer than their cancer-free wild-type littermates, 
suggesting that in the absence of cancer, reduced Mtbp 
expression conferred a survival benefit. These data 
suggest that the delayed presentation of lymphoma may 
reflect increased vitality of the Mtbp+/- mice, as 
lymphoma development occurred at younger ages in the 
wild-type cohort.  
 
In addition to increased longevity and modulated cancer 
development, long-lived Mtbp heterozygous mice 
exhibited a global trend toward elevated cellular 
metabolism in the liver.  While this may coincide with 
an overall increase in metabolism reported for Myc+/- 
mice [8], specific ties to aging have also been described.  
For example, caloric restriction, well known to improve 
longevity, has been previously shown to increase 
hepatic Gls expression [34]. Odc expression is elevated 
in younger livers and been implicated in the capacity for 
hepatic repair and regeneration [35]. We also observed 
increased expression of Pgc1α and Pgc1β, which 
regulate mitochondrial biogenesis and function. Their 
reduced expression with aging has been associated with 
many age-related pathologies [36]. Collectively, 
increased expression of these metabolic markers 
suggests retained vitality in the livers of old Mtbp+/- 
mice, which coincides with the elevated expression of 
the well-known anti-aging gene Sirt1 [5].   
 
The increased expression of metabolic genes observed 
in aged Mtbp+/- livers was largely sporadic or nearly 
absent in skeletal muscle and brown fat. Interestingly, 
the absence of global metabolic changes in the skeletal 
muscle and brown fat of Mtbp+/- mice compared to the 
global increase observed in the liver also matches with a 
lack of elevated Sirt1 expression observed in these 
tissues. Moreover, the lack of increase in metabolic 
markers and the downward trend in Pgc1α and Pgc1β 
expression in skeletal muscle of Mtbp+/- mice support 
their similar performance in open field and rota-rod 
testing compared to wild-type controls. This is in 
contrast to Myc+/- mice, which showed metabolic 
changes in skeletal muscle and improved rota-rod 
performance [8].  The reasons for the differential 
response to decreased Mtbp expression in the liver 
compared to skeletal muscle and adipose tissue is 
unclear at this time. However, a microarray analysis of 
liver, skeletal muscle, and adipose tissue in old Myc+/+ 
and Myc+/- revealed the highest number of differentially 
expressed genes occurred in the liver [8]. Thus, future 
studies focused on the tissue-specific benefits of 
reduced Mtbp and/or Myc expression would be 
important. 
 
Collectively, the data suggest Mtbp impacts longevity 
and cellular metabolism, particularly in the liver.  These 
results are in line with a recent report on Myc [8] as 
well as our previous reports indicating Mtbp is a 
positive regulator of Myc transcriptional activity [22, 
23].  However, the effect of Myc heterozygosity appears 
broader than the effects observed for Mtbp 
heterozygosity. For example, decreased Myc expression 
resulted in smaller body size, improved rota-rod 
performance, reduced circulating IGF-1, and lower 
serum cholesterol [8].  The precise reason for these 
differences is unclear at this time, although we have 
previously demonstrated Mtbp expression does not alter 
protein expression of Myc [22, 23], but did change the 
transcriptional activity of Myc. Part of the downstream 
effects of Myc are mediated through direct binding to or 
displacement of other factors at DNA, such as Miz1, 
NFY, C/EBPβ, SP1, and Foxo3A [7, 37, 38]. Myc also 
regulates transcriptional elongation through recruitment 
of P-TEFb [39, 40].  It is unknown how Mtbp 
expression impacts these functions of Myc or whether 
these functions of Myc change as animals age. 
Moreover, it is possible Mtbp may only orchestrate a 
sub-set of Myc’s overall transcriptional activity and 
may have Myc-independent functions.  Therefore, 
additional research is needed on the interaction between 
Mtbp and Myc, and Mtbp itself, to better understand the 






Mtbp+/- [29] and littermate-matched Mtbp+/+ C57Bl/6 
mice of both genders were generated through 
interbreeding and were housed together. For survival 
analysis, mice were sacrificed after meeting humane 
end-of-life criteria. Necropsy with tissue collection was 
performed and tissues were evaluated by a board-
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certified veterinary pathologist (K.B.) in a blinded 
manner. For analysis of healthy aged mice (29 months-
old), the mice were starved for 5 hours and crown-to-
rump length was measured. Blood was collected and 
analyzed for blood glucose levels with Accu-chek test 
strips (Roche Diagnostics, Indianapolis, IN, USA; [41], 
centrifuged and plasma frozen for later analysis. Mice 
were sacrificed by cervical dislocation. Liver and 
gastrocnemius muscle were frozen with a Wallenburg 
clamp pre-cooled in liquid nitrogen as previously 
described [42]. Brown fat pads were collected and 
frozen. Tissues were kept at -80oC until analysis. 
Femurs were collected and measured with electronic 
calipers. Experiments were approved by the Vanderbilt 
Institutional Animal Care and Use Committee and 
followed all federal and state rules and regulations.   
 
Quantitative real-time PCR (RT-PCR) 
 
Total RNA was isolated from frozen tissues, cDNA was 
generated, and qRT-PCR was performed as previously 





Analysis of serum was performed by the Mouse 
Metabolic Phenotyping Center in the Hormone Assay 
and Analytical Services and the Lipids and Lipoproteins 
Subcores at Vanderbilt University. Insulin levels were 
measured with a radioimmunoassay (SRI-13K, EMD 
Millipore, Billerica, MA, USA). IGF-1 levels were 
measured using a magnetic Luminex screening assay 
(LXSAMSM-01, R&D Systems, Minneapolis, MN, 
USA). Triglyceride and cholesterol levels were 
measured using Raichem reagents (R80035 and 




Explorative locomotion or open field testing was 
performed using a 48 channel IR controller (ENV-520, 
Med Associates Inc., St. Albans, Vermont) on young (6 
months-old) and aged (21 months-old) mice. On two 
different days, mice were placed in the open field, the 
total distance traveled was recorded for 1 hour and the 
average of the two measurements was reported. 
Additionally, on three consecutive days, mice were 
placed on a five-lane accelerating rota-rod (47600, Ugo 
Basile, Varese, Italy) for three sequential trials 
separated by 10 minutes of rest. The rota-rod 
accelerated from 4 to 40 rpm over 3 minutes with a cut-
off time of 3 minutes.  Time running on the rota-rod 
was determined by using pressure sensors to detect falls 
or by observing >3 consecutive rotations of the mouse 
around the rod. The average times from day 3 were 




A log-rank test was used to calculate significance in 
Figure 1 and Supplemental Figure S1. Analysis for 
Figure 1E and Supplemental Figure S1 was performed 
with JMP statistical software (v12.2.0). Student’s t-test 
was used to calculate significance for data in Figures 2-
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Real Time PCR Primers 
 
Cad-F – AACTGCGTAGGCTTCGACCATACA 
Cad-R – AATCAATGCGGGTGAGCTCGTAGA 
Gls [1] 
Gls-F – TTCGCCCTCGGAGATCCTAC 
Gls-R – CCAAGCTAGGTAACAGACCCT 
Hk2 [2] 
Hk2-F – TGATCGCCTGCTTATTCACGG 
Hk2-F – AACCGCCTAGAAATCTCCAGA 
Ncl-F – ACTGGAAAGACCAGCACTTGGAGT 
Ncl-R – CCCTTTAGGTTTGCCATGTGGGTT 
Odc-F – GCATGTGGGTGATTGGATGCTGTT 
Odc-R – TTGCCACATTGGCCGTGACATTAC 
Pcg1a-F – GGATGAATACCGCAAAGAGC 
Pcg1a-R – GGTAGGTGATGAAACCATAGC 
Pcg1b [3] 
Pcg1b-F – TCCTGTAAAAGCCCGGAGTAT 
Pcg1b-R – GCTCTGGTAGGGGCAGTGA 
Sirt1 [4] 
Sirt1-F – ACCTCCCAGACCCTCAAGC 
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Figure  S2.  Male  and  female  Mtbp  heterozygous  mice
have a decreased instantaneous death rate. Instantaneous
death  rate  plotted  for  males  (A),  log‐rank  P  =  0.0166,  Chi‐
sq=5.74, df=1) and females (B), log‐rank P = 0.0439, Chi‐sq=4.06,
df=1). The number of mice in each group denoted by n. 
Figure  S3.  Mtbp  heterozygosity  does  not  significantly  alter 
locomotor activity  in young mice.  (A) Six month‐old Mtbp+/+  (+/+; 
circle) and Mtbp+/‐ (+/‐; square) mice were placed in an open field cage 
and  the  total distance  traveled  in one hour was recorded using a  laser
grid and averaged  for  two  consecutive days  (p= 0.1772).  (B) After  two 
days of training, the time +/+ and +/‐ mice spent on an accelerating rota‐
rod  recorded and averaged  from  three consecutive  trials  separated by
10 minutes of rest (p=0.3359). P values calculated with student’s t‐tests. 
Error bars represent standard error of the mean. 
